Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income | -$74.6M | -$94.3M | -$178M |
| Net income | -$69.3M | -$80.5M | -$166M |
| EPS (diluted) | -$32.38 | -$2.56 | -$4.32 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$55.8M | -$70.2M | -$161M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $150M | $74.3M | $45.5M |
| Total assets | $163M | $275M | $333M |
| Total liabilities | $11.8M | $17.3M | $25.9M |
| Shareholders' equity | -$153M | $258M | $307M |
| Retained earnings | -$158M | -$238M | -$405M |
| Shares (wtd avg diluted) | 2.14M | 31.5M | 38.5M |
Every figure is extracted from ArriVent BioPharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.